At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura, a ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment ...

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a ...

Schizophrenia is a complex psychiatric disorder marked by positive, negative and cognitive symptoms, many of which are poorly addressed by current dopamine-blocking antipsychotics. Preclinical studies ...

GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts ...

UNC researchers discovered how a key step in cell signaling works by showing exactly how G proteins detach from receptors ...

A second dose of an investigational nasal spray formulation of mebufotenin benzoate -- a tryptamine psychedelic -- offered ...

An international team involving the Institute of Chemical Research, a joint center of the University of Seville and the ...

(RTTNews) - Axsome Therapeutics Inc. (AXSM) has secured exclusive global rights to AZD7325, a novel oral GABAA receptor a2,3 subtype-selective positive allosteric modulator, from AstraZeneca. The ...

Neurocrine Biosciences (NBIX) may be undervalued, with strong Ingrezza growth, Crenessity's billion-dollar potential, and a ...